Just to remind everbody out in 'cyberland' what AIMM is all about.
AutoImmune Inc. is developing a new class of orally administered drugs for the treatment of autoimmune diseases. The
Company's products are oral, well tolerated, very safe and designed for long-term treatment. AutoImmune has a deep pipeline
of products in clinical development. The Company's two lead products, for multiple sclerosis and rheumatoid arthritis, will
reach major milestones in early 1997.
THE TECHNOLOGY
In autoimmune diseases, the immune system mistakenly identifies the body's own healthy cells as foreign and mounts an attack
against these healthy cells, causing disease. AutoImmuneOs products are designed to stimulate the body's natural defense
mechanisms to shut down the attack without broadly suppressing the immune system.
INVESTMENT FEATURES
Major clinical milestones in early 1997 for multiple sclerosis and rheumatoid arthritis products
Large, underserved markets
Oral, safe products ideal for long-term treatment
Collaboration with Eli Lilly for Type I diabetes product
Enough cash in place to complete development of lead products
U.S. patients with multiple sclerosis: 350,000
Market opportunity: $1.3 billion
Trial completed: March 1997
Myloralr for Multiple Sclerosis
Multiple sclerosis (MS) is the most common chronic neurologic disability among young adults. In MS patients, the immune
system destroys the tissue that insulates nerve cells, causing a progressive decline in function.
Results from final human testing expected in early 1997
$1.3 billion market in the U.S. alone
Myloral" is positioned to be the first oral drug to treat MS
Only two competitive products currently approved for MS -- both require frequent injections and have side effects
U.S. patients with rheumatoid arthritis: 2.5 million
Market opportunity: 1.0 billion
Advanced trial data expected: First Qtr. 97
Colloralr for Rheumatoid Arthritis
In rheumatoid arthritis, the immune system mistakenly attacks the cartilage that cushions bone joints. Disabling pain and
inflammation can result, leaving the patient unable to move freely.
Results from three advanced clinical trials expected in early 1997
$ 1.0 billion market potential
Current treatments for rheumatoid arthritis cause serious/dangerous side effects and have limited effectiveness
Excellent safety profile makes Colloralr ideal for use early in the disease process
U.S. patients with Type I diabetes: 1 million
Market opportunity: $600 million
Partner: Eli Lilly
AI-401 for Type I Diabetes
AutoImmune is developing a treatment for insulin-dependent (Type I) diabetes. Patients with Type I diabetes require insulin
injections to control sugar metabolism. This treatment produces inconsistent therapeutic results and fails to prevent the deadly,
long-term complications of the disease.
$40-million partnership with pharmaceutical leader, Eli Lilly and Company
300-patient clinical trial ongoing to show AI-401 can slow or prevent the progression of the disease
Other Applications
Uveitis
AutoImmune expects to begin clinical trials of AI-301 for uveitis in 1997. Uveitis, an inflammatory degenerative eye disorder
which can lead to blindness, affects approximately 200,000 patients worldwide. AutoImmune believes that AI-301 could act
as a potential replacement for more toxic therapies currently on the market.
Transplant Rejection
AutoImmune plans to begin human testing of AI-502 for transplant patients in the fourth quarter of 1996. Currently approved
treatments reduce the risk of transplant rejection, but suppress the entire immune system, leaving the patient highly susceptible
to infection. If successful, AI-502 could increase the patient's chances of successful transplants without compromising the
patient's entire immune system.
Other Disease Targets
AutoImmune's proprietary technology may be applicable for treating many other autoimmune and inflammatory diseases such
as: Crohn's Disease
Psoriasis
Atherosclerosis
Alzheimer's Disease
AutoImmune Inc.
128 Spring Street
Lexington, MA 02173
Tel: 617-860-0710 Fax: 617-860-0705
autoimmuneinc.com |
